Navigation Links
NIH to fund development of K-12 neuroscience education programs
Date:9/27/2011

Eight investigators across the United States will receive funding over the next five years to develop innovative neuroscience education programs for K-12 students and their teachers. Activities described within some proposals include using touch tablet technology to teach neurobiology, and the creation of a 1,400-square-foot interactive learning center. These grants are funded by the NIH Blueprint for Neuroscience Research Science Education Award and the Science Education Partnership Award Program of the National Center for Research Resources (NCRR). The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health and administrator of the grants, made the announcement.

These educational programs aim to increase science literacy and understanding as well as an interest in science among K-12 students and their teachers. This is particularly important, since the most recent trends published by the U.S. Department of Education indicate that U.S. eighth graders score lower than students from nine other countries in science knowledge and skills. The project seeks to close this gap as well as fulfill the NIH mission to ensure that adequate numbers of students are entering science education tracks and eventually pursuing careers in biomedical science.

"Creative strategies are needed to ensure that the United States maintains its competiveness in the scientific field," said NIDA Director Nora D. Volkow, M.D. "Since neuroscience cuts across many different disciplines and can help in understanding all kinds of behavior, it is the ideal vehicle for capturing people's interest and engaging them in scienceat any age."

Awardees are as follows:

Steve Snyder, Ph.D., The Franklin Institute, Philadelphia
Project: Neuroscience in Your World: A Partnership for Neuroscience Education Across the K-12 Spectrum
This collaborative effort between The Franklin Institute and the Center for Neuroscience and Society
'/>"/>

Contact: NIDA Press Team
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Belly fat linked to development of asthma
2. BPA alters development of in vitro ova and could increase risk of Down syndrome
3. NIDA Avant-Garde-Medications Development Award winners announced
4. Transformative NIH grant will support development of tissue regeneration therapeutics
5. New strategy likely to speed drug development for rare cancers
6. Prenatal exposure to phthalates linked to decreased mental and motor development
7. Memory Development Incomplete Until Adulthood: Study
8. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
9. Sweet insight: Discovery could speed drug development
10. AMRI receives NIH contract award for development of pre-clinical drug candidates
11. NIH Blueprint empowers drug development for nervous system disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... 2015 What does community do? , ... community comes together to plant gardens, to teach young ... awareness of critical issues. Community invites everyone to help ... , "What Community Does" was commissioned by The Denver ... and released during the foundation’s Annual Celebration in May. ...
(Date:5/29/2015)... Rhode Island (PRWEB) May 29, 2015 ... 7, 2015. The event, now closed to new registration, ... Fort Adams. This exciting competitive running event demonstrates ... organizations to create a public benefit – in this ... scenic coastal views around the famed Ocean Drive and ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... 2015 According to a recent HealthDay article, ... workers has a substance abuse problem - the data, which ... adults with full-time jobs, revealed that 9.5% of those workers ... (1) The National Council on Alcoholism and Drug Dependence (NCAAD) ... an estimated 70% of the 14.8 million illicit drug users ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... Caused Public Health CrisisEditor,s Note: Complete report including ... . WASHINGTON, Jan. 13 The American Lung ... 2008 report today, which includes a report ... federal laws to protect citizens from tobacco caused ...
... groundbreaking case that could,affect one-third of American families, Cook ... a 10 month old child with a severe heart,condition ... also gave the,father custody of his 3 year old ... unusual because most courts have not recognized stepfathers,as having ...
... Tenn., Jan. 13 The National Eczema Association (NEA) ... and Theraplex Clear Lotion .The NEA Seal ... Sensitive-Skin Education (EASE) program, which is intended to improve ... eczema and sensitive skin. "These products met our criteria ...
... meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical has ... season beginning in August. , ... (Vocus) January 13, ... Flu Vaccine for the 2009-2010 flu season. They ...
... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ... Julia M. Fisher, Western Medical Product Manager. , ... Westlake, OH (PRWEB) ... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ...
... New research out of Wake Forest University Baptist Medical ... used to relieve symptoms of cough and congestion, may ... , The study appears in this month,s issue ... American College of Chest Physicians, and reports that the ...
Cached Medicine News:Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 2Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 3Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Low Cost Oxygen Regulator: Pay Less For Quality 2Health News:Popular cold and cough treatment may create respiratory distress in young children 2Health News:Popular cold and cough treatment may create respiratory distress in young children 3
(Date:5/29/2015)... May 29, 2015 /CNW/ - Covalon Technologies Ltd. (the ... technologies company, is delighted to announce its financial ... 2015, which includes revenue for three months of ... $264,340. Revenue from advanced wound care product sales for ... increased 24% to $1,742,672 compared to $1,400,065 for ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... May 02, 2007 /PRNewswire/ -- Ceregene, Inc.,today presented interim ... gene therapy product designed to deliver nerve growth,factor (NGF) ... follow-up, the results for the six patients who received,CERE-110 ... the,therapy was well tolerated, and an interim analysis suggested ...
... CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - ... sclerosis (RRMS),patients treated with COPAXONE(R) (glatiramer ... experienced a,90 percent reduction in magnetic ... their baseline. These benefits were,achieved early ...
Cached Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: